HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

Nature Medicine

Volumn 1, Issue 1, 1995, Pages 59-64

  Rowland Jones, Sarah ^a   Sutton, Julian ^a   Ariyoshi, Koya ^b   Dong, Tao ^a   Gotch, Frances ^a   McAdam, Steve ^a   Whitby, Denise ^c   Sabally, Sehu ^b   Gallimore, Awen ^a   Corrah, Tumani ^b   Takiguchi, Masafumi ^d   Schultz, Thomas ^c   McMichael, Andre ^a   Whittle, Hilton ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIGEN; HLA B35 ANTIGEN;

ANTIGEN PRESENTATION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTITUTION;

AFRICA; AFRICA SOUTH OF THE SAHARA; ANTIBODIES; BEHAVIOR; BIOLOGY; DEVELOPING COUNTRIES; DISEASES; ENGLISH SPEAKING AFRICA; EXAMINATIONS AND DIAGNOSES; GAMBIA; HIV INFECTIONS; IMMUNITY; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; LABORATORY EXAMINATIONS AND DIAGNOSES; LABORATORY PROCEDURES; PHYSIOLOGY; PROSTITUTES; RESEARCH REPORT; SEX BEHAVIOR; VIRAL DISEASES; WESTERN AFRICA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GAMBIA; HIV ANTIGENS; HIV-1; HIV-2; HLA-B35 ANTIGEN; HUMAN; IMMUNITY, CELLULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0028944192     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm0195-59     Document Type: Article

References (60)

1. Ho, D. D., Moudgil, T. & Alam, M, Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N. Engl. J. Med. 321, 1621-1625 (1989).
2. Schecter, M. T. et al. HIV-1 and the aetiology of AIDS. Lancet 341, 658-659 (1993).
3. Clerici, M. et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J. infect DiS. 165, 1012-9 (1992).
4. Clerici, M. & G. Shearer. A Th1 → Th2 switch is a critical step in the aetiology of HIV infection. Immunol. Today 14, 107-111 (1993).
5. Clerid, M. et al. Cellular immune factors associated with mother-to-infant transmission of HIV. AIDS 7, 1427-33 (1993).
6. Clerici, M. et al. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood. J. AM. A. 271, 42-6 (1994).
7. Levy, J, A. HIV pathogenesis and long-term survival. AIDS 7, 1401-1410 (1993).
8. Miedema, F., L. Meyaard & M. R. Klein. Protection from HIV or AIDS? Science 262, 1074-1075 (1993).
9. Salk, J., P. A. Bretscher, P. L. Salk, M. Clerici and G. M. Shearer. Protection from HIV or AIDS? Science 262, 1075-1076 (1993).
10. Cheynier, R. et al. Cytotoxic T lymphocyte responses in the peripheral blood of children bom to HIV-l-lnfected mothers. Eur. f. Immunol. 22, 2211-2217 (1992).
11. Rowland-Jones, S. L. et al. HIV-specific CTL activity in an HIV-exposed but uninfected infant. Lancet 341, 860-861 (1993).
12. Aldhous, M. C., K. C. Watret, J. Y. Mok, A. G. Bird and K. S. Froebel. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection. Clin. Exp. Immunol. 97, 61-7 (1994).
13. Langlade-Demoyen, P., N. Ngo-Glang-Huong, F. Ferchal and E. Oksenhendler. HIV nef-speciflc cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J. clin. Invest. 93, 1293-1297 (1994).
14. Walker, B. D. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328, 345-8 (1987).
15. Plata, F. et al. AIDS virus specific cytotoxic T lymphocytes in lung disorders. Nature 328, 348-351 (1987).
16. Carmichael, A., X. Jin, P. Sissons and L. Borysiewicz. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-l)-speciflc cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J. exp. Med. 177, 249-56 (1993).
17. Kalams, S. A. et al. Longitudinal analysis of TCR gene usage by HIV-1 envelope-specific CTL clones reveals a limited TCR repertoire. J. exp. Med. 179, 1261-1271 (1994).
18. Mabey, D. C. W. et al. Human retroviral infections in The Gambia, prevalence and clinical features. Br. med. J. 296, 83-86 (1988).
19. Wilkins, A. et al. Trends in HIV-1 and HIV-2 infection in The Gambia. AIDS 5, 1529-30 (1991).
20. Pickering, H., M. Quigley, J. Pepin, J. Todd & A. Wilkins. The effects of post-test counselling on condom use among prostitutes in The Gambia. AIDS 7, 271-3 (1993).
21. Nixon, D. F. et al. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336, 484-487 (1988).
22. Elliott, T., M. Smith, P. Driscoll and A. McMichael. Peptide selection by class I molecules of the MHC. Cun. Opin. Immunol. 3, 854-866 (1993).
23. Allsopp, C. E. et al. Interethnic genetic differentiation in Africa: HLA class I antigens in The Gambia. Am. J. hum. Genet. 50, 411-21 (1992).
24. Martinon, F., E. Gomard, C. Hannoun and J.-P. Levy. In vitro human CTL responses against influenza A virus can be induced and selected by synthetic peptides. Eur. J. Immunol. 21, 2171-2176 (1990).
25. Hill, A. V. S. et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360, 434-439 1992.
26. Kos, F. J. and A. Mullbacher. Induction of primary anti-viral cytotoxic T cells by in vitro stimulation with short synthetic peptide and interleukin-7. Eur. J. Immunol. 22, 3183-5 1992.
27. Neefjes, J. J., B. S. Breur-Vriesendorp, G. A. Van Seventer, P. Ivanyi and H. L. Ploegh. An improved biochemical method for the analysis of HLA class I antigens. Definition of new HLA class I subtypes. Hum. Immunol. 16, 169-181 (1986).
28. Culmann, B., E. Gomard and M.-P. Kieny. Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 nef protein. J. Immunol. 146, 1560-1565 (1991).
29. Gotch, F. et al. Cytotoxic T cells in HIV-2 seropositive Gambians. Identification of a virus-specific MHC-restricted peptide epitope. J. Immunol. 151, 3361-9 (1991).
30. Schulz, T. F. et al. Biological and molecular variability of HIV-2 isolates from The Gambia. J. Virol. 64, 5177-5182 (1990).
31. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice and T. A. Steitz. Crystal structure at 3. 5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-1790 (1992).
32. Shugars, D. C. et al. Analysis of HIV-1 nef gene sequences present in vivo. J. Virol. 67, 4639-4650 (1993).
33. Silver, J., T. Maudru, K. Fujita and R. Repaske. An RT-PCR assay for the enzyme activity of reverse transcriptase capable of detecting single virions. N. A. R. 21, 3593-3594 (1993).
34. Safrit, J. T., C. A. Andrews, T. Zhu, D. D. Ho & R. A. Koup. Characterization of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte clones isolated during acute seroconversion: recognition of autologous virus sequences within a conserved immunodominant epitope. J. exp. Med. 179, 463-72 (1992).
35. Burrows, S. R., R. Khanna, J. M. Burrows and D. J. Moss. An alloresponse in humans is dominated by CTL cross-reactive with a single EBV CTL epitope, implications for graft-versus-host disease. J. exp. Med. 179, 1155-1161 (1994).
36. Carbone, F. R., M. W. Moore, J. M. Shell and M. J. Bevan. Induction of CTL by primary in vitro stimulation with peptides. J. exp. Med. 167, 1767-1779 (1989).
37. Macatonia, S. E., P. M. Taylor, S. C. Knight and B. A. Askonas. Primary stimula tion by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J. exp. Med. 1255-1264 (1989)
38. De Bruijn, M. et al. Mechanisms of induction of primary virus-specific cytotoxic T lymphocyte responses. Eur. J. Immunol. 22, 3013-20 (1992).
39. Schild, H. et al. Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. exp. Med. 174, 1665-8 (1991).
40. Salk, J., P. A. Bretscher, P. L. Salk, M. Clerici and G. M. Shearer. A strategy for prophylactic vaccination against HIV. Science 260, 1270-1272, 1993.
41. Clerici, M. et al. T-cell proliferation to subinfectious S1V correlates with lack of infection after challenge of macaques. AIDS 8, 1391-1395, 1994.
42. Bretscher, P. A., G. Wei, J. N. Menon and H. Bieiefeldt-Ohmann. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 257, 539-542 (1992).
43. Markovitz, D. M. Infection with the human immunodeficiency virus type 2. Ann. intern. Med. 118, 211-8, (1993).
44. Simon, F. et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 7, 1411-1417(1993).
45. De Cock, K. M. et al. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. J. A. M. A. 270, 2083-6 (1993).
46. Robert-Guroff, M. et al. Cross-neutralization of human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus isolates. J. Virol. 66, 3602-8 (1992).
47. Pinto, L. A., M. Joao Covas and R. M. M. Victorino. T-helper cross reactivity to viral recombinant proteins in HIV-2-infected patients. AIDS 7, 1389-1391 (1993).
48. Nixon, D. F. et al. An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope. AIDS 4, 841-5 (1990).
49. Phillips, R. E. et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 354, 453-9 (1991).
50. Johnson, R. P., A. Trocha, T. M. Buchanan and B. D. Walker. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation. J. exp. Med. 175, 961-71 (1992).
51. Johnson, R. P., A. Trocha, T. M. Buchanan and B. D. Walker. Recognition of a highly conserved region of human immunodeficiency virus type 1 gpl20 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J. Virol. 67, 438-45 (1993).
52. George, J. R. et al. Prevalence of HIV-1 and HIV-2 mixed infections in Cote D'Ivoire. Lancet 340, 337-339 (1992).
53. Peeters, M. et al. Virological and PCR studies of HIV-l/HIV-2 dual infection in Cote d' Ivoire. Lancet 340, 339-340 (1992).
54. Leonard, G. et al. Characterisation of dual HIV-1 and HIV-2 serological profiles by PCR. AIDS 7, 1185-1189 (1993).
55. Mullbacher, A. The long-term maintenance of CTL memory does not require persistence of antigen. J. exp. Med. 179, 317-321 (1994).
56. Lau, L. L., B. D. Jamieson, T. Somasundaram and R. Ahmed. Cytotoxic T-cell memory without antigen. Nature 369, 648-52 (1994).
57. Gray, D. and P. Matzinger. T cell memory is shott-lived in the absence of antigen. J. exp. med. 174, 969-974 (1991).
58. Simmonds, P. et al. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J. Virol. 64, 864-72 (1990).
59. Beny, N. J. HIV-2 proviral load measured by quantitative PCR correlates with CD4+ lymphopaenia in HIV-2 infected Individuals. AIDS Research and Human Retroviruses. 8, 1031-1037 (1994).
60. Lee, S. et al. EBV isolates with the major HLA B35. øl-rstricted cytotoxic T lymphocyte epitope are prevalent in a highly B35. øl-positive African population. Ev. J. Immun. (in the press)